Boston Scientific (BSX)
(Delayed Data from NYSE)
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$81.60 USD
+0.23 (0.28%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $81.64 +0.04 (0.05%) 7:58 PM ET
2-Buy of 5 2
C Value B Growth F Momentum C VGM
Zacks News
Headquartered in Natick, MA and founded in 1979, Boston Scientific Corporation manufactures medical devices and products used in various interventional medical specialties worldwide. The company has adopted the organic as well as inorganic routes for success. Boston Scientific currently has 3 global reportable segments viz. Cardiovascular (39.6% of total revenue in 2019; up 10% organically from 2018), Rhythm and Neuro (28.1%; up 1%) and MedSurg (30.2%; up 10.6%).
Top Research Reports for AT&T, Home Depot & Cisco
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including AT&T (T), Home Depot (HD) and Cisco (CSCO).
Thermo Fisher (TMO) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Thermo Fisher (TMO) continues with its impressive performance momentum across analytical instrument businesses witnessing escalating global demand.
Can Strategic Alliances Aid LabCorp's (LH) Q2 Earnings?
by Zacks Equity Research
LabCorp (LH) is expected to gain traction from a solid LabCorp Diagnostics segment in Q2, courtesy of a favorable price, mix, tuck-in acquisitions and organic volume.
Can Rhythm and Neuro Aid Boston Scientific (BSX) Q2 Earnings?
by Zacks Equity Research
Boston Scientific (BSX) set to ride high on strength in Rhythm and Neuro business in Q2.
Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Boston Scientific (BSX) expects to consistently gain from impressive growth across all business lines and geographies.
Why You Should Add Boston Scientific (BSX) to Your Portfolio
by Zacks Equity Research
Boston Scientific's (BSX) agreement for Cryterion Medical buyout in the field of atrial fibrillation buoys investor optimism on the stock.
Is Boston Scientific (BSX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BSX) Outperforming Other Medical Stocks This Year?
Will Core Segmental Growth Aid Stryker (SYK) in Q2 Earnings?
by Zacks Equity Research
Stryker's (SYK) strong segmental performance and acquisition-driven strategy are likely to drive Q2 earnings.
Boston Scientific to Buy Cryterion Medical to Widen EP Suite
by Zacks Equity Research
Boston Scientific (BSX) forges ahead with initiatives to strengthen its hold in the high-potential EP market.
Here's Why You Should Invest in Baxter (BAX) Stock Right Now
by Zacks Equity Research
Baxter's (BAX) raised 2018 guidance and strong international presence make it a lucrative pick.
Zacks.com featured highlights include: General Motors, Boston Scientific, T. Rowe Price, AMC Networks and Celanese
by Zacks Equity Research
Zacks.com featured highlights include: General Motors, Boston Scientific, T. Rowe Price, AMC Networks and Celanese
5 ROE Stocks to Buy as Proposed Auto Tariffs Rattle Markets
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed
by Zacks Equity Research
Zacks.com featured highlights include: Anthem, Merit Medical, Boston Scientific, Grand Canyon and PetMed
7 GARP Stocks to Scoop Up for Maximum Returns
by Zacks Equity Research
Growth at a reasonable price or GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount.
LZAGY vs. BSX: Which Stock Is the Better Value Option?
by Zacks Equity Research
LZAGY vs. BSX: Which Stock Is the Better Value Option?
Will Walgreens (WBA) Q3 Earnings Gain From Overall Strength?
by Zacks Equity Research
Walgreens Boots' (WBA) sales rise at the Retail Pharmacy USA segment on account of tie-ups along with strength in other businesses buoys optimism.
Has Boston Scientific (BSX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is Boston Scientific Corporation (BSX) Outperforming Other Medical Stocks This Year?
Tap Cardiovascular Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing cardiovascular devices market.
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese
by Zacks Equity Research
Zacks.com featured highlights include: General Motors, Boston Scientific, Antero NRG, AMC and Celanese
Top 5 ROE Stocks to Buy as Trump Keeps Trade War Fears Alive
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Boston Scientific Up on Possible Takeover Bid by Stryker
by Zacks Equity Research
Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.
Company News For Jun 12, 2018
by Zacks Equity Research
Companies In The News are: EVHC,BSX,SYK,SRE,ADNT
Boston Scientific (BSX) Looks Good: Stock Adds 7.4% in Session
by Zacks Equity Research
Boston Scientific (BSX) shares rose more than 7% in the last trading session, amid huge volumes.